- Home
- TXG
as 07-26-2024 4:00pm EST
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 3.0B | IPO Year: | 2019 |
| Target Price: | $32.75 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.28 - $63.57 | Next Earning Date: | 08-08-2024 |
| Revenue: | $625,448,000 | Revenue Growth: | 16.64% |
| Revenue Growth (this year): | 9.36% | Revenue Growth (next year): | 15.05% |
Stock Insider Trading Activity of 10x Genomics Inc. (TXG)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McAnear Justin J. | TXG | Chief Financial Officer | May 22 '24 | Sell | $24.30 | 2,936 | $71,355.37 | 146,203 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | May 22 '24 | Sell | $24.30 | 4,877 | $118,528.66 | 889,641 | SEC Form 4 |
| Hindson Benjamin J. | TXG | See Remarks | May 22 '24 | Sell | $24.30 | 4,087 | $99,328.81 | 350,055 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Mar 4 '24 | Sell | $44.00 | 4,660 | $205,020.89 | 842,900 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 22 '24 | Sell | $46.34 | 2,821 | $130,737.27 | 847,560 | SEC Form 4 |
| McAnear Justin J. | TXG | Chief Financial Officer | Feb 22 '24 | Sell | $46.34 | 1,865 | $86,432.12 | 95,240 | SEC Form 4 |
| Hindson Benjamin J. | TXG | See Remarks | Feb 22 '24 | Sell | $46.34 | 2,613 | $121,097.66 | 283,059 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 15 '24 | Sell | $48.58 | 3,300 | $160,300.14 | 852,081 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 15 '24 | Sell | $49.43 | 1,700 | $84,032.02 | 850,381 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 9 '24 | Sell | $49.53 | 1,000 | $49,530.10 | 855,381 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Jan 16 '24 | Sell | $45.10 | 2,965 | $133,711.72 | 857,416 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Jan 16 '24 | Sell | $45.65 | 1,035 | $47,244.33 | 856,381 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Dec 14 '23 | Sell | $54.39 | 300 | $16,316.01 | 847,146 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Dec 14 '23 | Sell | $55.15 | 1,700 | $93,749.05 | 845,446 | SEC Form 4 |
| Wilbur James | TXG | Chief Commercial Officer | Nov 22 '23 | Sell | $43.34 | 3,464 | $150,118.33 | 83,342 | SEC Form 4 |
| Hindson Benjamin J. | TXG | See Remarks | Nov 22 '23 | Sell | $43.34 | 3,449 | $149,468.28 | 277,338 | SEC Form 4 |
| McAnear Justin J. | TXG | Chief Financial Officer | Nov 22 '23 | Sell | $43.34 | 1,679 | $72,762.32 | 97,105 | SEC Form 4 |
| Wilbur James | TXG | Chief Commercial Officer | Nov 20 '23 | Sell | $42.09 | 14,718 | $619,493.87 | 86,806 | SEC Form 4 |
| Saxonov Serge | TXG | Chief Executive Officer | Nov 14 '23 | Sell | $39.52 | 2,000 | $79,040.60 | 854,926 | SEC Form 4 |
Latest 10x Genomics Inc. News
TXG Breaking Stock News: Dive into TXG Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Canaccord Genuity Adjusts Price Target on 10x Genomics to $32 From $50, Maintains Buy Rating
MT Newswires
4 days ago
10x Genomics Shares Rise Following Jefferies Upgrade
MT Newswires
5 days ago
Jefferies Upgrades 10x Genomics to Buy From Hold, Price Target is $24
Insider Monkey
5 days ago
10x Genomics, Inc. (TXG): Hedge Funds Think This Stock Will Skyrocket
MT Newswires
8 days ago
10x Genomics Shares Fall After JPMorgan Downgrade
MT Newswires
8 days ago
BofA Securities Adjusts Price Target on 10x Genomics to $25 From $36
MT Newswires
9 days ago
JPMorgan Downgrades 10x Genomics to Neutral From Overweight, Adjusts Price Target to $20 From $40
Zacks
9 days ago
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
Compare TXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.